Research map: Aumolertinib Versus Osimertinib as First‐Line Treatment for EGFR ‐Mutant Non‐Small Cell Lung Cancer: A Retrospective Real‐World Multicenter Study

Back to the article

Papers in this map

  1. Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer · Jean‐Charles Soria · 2017 · 5482 citations · Cited by this paper
  2. Helicobacter pylori Infection and the Risk of Biliary Tract and Pancreatic Cancers: Subsite‐Specific Associations in a Japanese Population · 2026 · Related
  3. AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations · Shun Lü · 2022 · 302 citations · Cited by this paper
  4. Sodium‐Glucose Cotransporter 2 Inhibitors and Cancer Risk in Patients With Type 2 Diabetes Mellitus: An Active Comparator, New‐User Cohort Study · 2026 · Related
  5. Lung Cancer in People’s Republic of China · Shugeng Gao · 2020 · 251 citations · Cited by this paper
  6. Unraveling the Plasma Extracellular Vesicles Proteome: Predictors of Resistance in Immunotherapy of Advanced Melanoma · 2026 · Related
  7. Insights into the Aberrant Activity of Mutant EGFR Kinase Domain and Drug Recognition · K.S. Gajiwala · 2012 · 202 citations · Cited by this paper
  8. The Optimal Lung Cancer Ct Screening Strategy: A Cost‐Effectiveness Study Incorporating Nelson Evidence, Evolving Cost of Treatment and Smoking Cessation Interventions · 2026 · Related
  9. Emerging therapies for non-small cell lung cancer · Chao Zhang · 2019 · 165 citations · Cited by this paper
  10. The Circulating Cholangiocarcinoma Protein Biomarkers CRP and MASP2 Also Predict Gallbladder Cancer Risk · 2026 · Related
  11. Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial · James Chih‐Hsin Yang · 2020 · 163 citations · Cited by this paper
  12. Obesity‐Driven Early‐Onset Colorectal Cancer: Mechanistic Insights and Emerging Clinical Implications · 2026 · Related
  13. Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals · Jianquan Zhu · 2008 · 128 citations · Cited by this paper
  14. Changing the History of Science—An Editorial Perspective on Critical Developments in Current Citation Practice, “Forgetting” the Pioneers of Scientific Discoveries · 2026 · Related
  15. Osimertinib plus platinum–pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study · David Planchard · 2021 · 70 citations · Cited by this paper
  16. Targeted Therapy and Oral Chemotherapy as Maintenance Treatment in Pediatric Very‐High‐Risk and High‐Risk Rhabdomyosarcoma: A Retrospective Study of Efficacy and Safety · 2026 · Related
  17. Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC · Yvette N. Lamb · 2021 · 69 citations · Cited by this paper
  18. Neoadjuvant Chemotherapy Versus Upfront Surgery for cT2N1 or cT3a ‐ bN0 ‐1 Middle‐High Rectal Cancer · 2026 · Related
  19. Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer · Roy S. Herbst · 2025 · 65 citations · Cited by this paper
  20. HPV Serology and Circulating Viral DNA for Detection, Genotyping, and Measurement of Disease Burden in Oropharyngeal Cancer · 2026 · Related
  21. Predictive and Prognostic Potential of TP53 in Patients With Advanced Non–Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial (CTONG 0901) · Xiang-Meng Li · 2020 · 64 citations · Cited by this paper
  22. Gefitinib Plus Chemotherapy vs Gefitinib Alone in Untreated EGFR -Mutant Non–Small Cell Lung Cancer in Patients With Brain Metastases · Xue Hou · 2023 · 57 citations · Cited by this paper
  23. Genetic differences between smokers and never-smokers with lung cancer · Piotr Kuśnierczyk · 2023 · 46 citations · Cited by this paper
  24. TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy—EGFR mutated non-small cell lung cancer IV patients treated with osimertinib · Julia Roeper · 2022 · 39 citations · Cited by this paper
  25. The Predictive Values of Advanced Non-Small Cell Lung Cancer Patients Harboring Uncommon EGFR Mutations—The Mutation Patterns, Use of Different Generations of EGFR-TKIs, and Concurrent Genetic Alterations · Jiarong Tan · 2021 · 22 citations · Cited by this paper
  26. Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations · Qihua He · 2021 · 18 citations · Cited by this paper
  27. Current and Emerging Options in the Management of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Considerations in the Elderly · Gabriele Minuti · 2015 · 10 citations · Cited by this paper
  28. The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study · Wen‐Chien Cheng · 2024 · 10 citations · Cited by this paper
  29. Clinical efficacy and safety analysis of aumolertinib in real-world treatment of EGFR-mutated advanced non-small-cell lung cancer · Xiaojuan Zhang · 2024 · 7 citations · Cited by this paper
  30. Are 19del and L858R really different disease entities? · Seoree Kim · 2024 · 6 citations · Cited by this paper
  31. Comprehensive management strategies for amivantamab-induced toxicities and review of the literature · Furkan Ceylan · 2025 · 6 citations · Cited by this paper

Source: OpenAlex (CC0)